CHASE, the outsourced commercialisation partner to the UK life sciences sector has acquired Medacy, a provider of quality pharmacist-led clinical services to the NHS.
Medacy works with over 100 GP practices, federations, primary care networks (PCNs) and hospital trusts across the NHS to support the growing demand for clinical pharmacists.
Clinical pharmacists are growing in number, prevalence and strategic importance across the UK, with each of England’s 1,250 PCNs likely to employ up to five clinical pharmacists by 2024. The NHS Long Term Plan and the NHS People Plan have committed to investing in this “essential role”.
Medacy, powered by CHASE’s support and recruitment engines, will now be able to offer its high-quality pharmacist-led clinical services to more NHS settings. At the same time, CHASE will strengthen its expert-led collaborative working and donations and grants solutions by adding remote patient reviews and utilising Medacy’s NHS network and expertise.
Graham Hawthorn, Managing Director of CHASE said, “this is an exciting moment which will fuel growth for both companies. Our clients are seeking first-hand insights into how the NHS is changing and wants to engage with industry; this acquisition really enables us to deliver that.
We’re also seeing increasing demand for our collaborative working solutions, and they will go from strength to strength with the added expertise of Shaun and his fantastic team.”
Shaun Hockey, Managing Director of Medacy, commented, “I’m delighted that Medacy is joining forces with CHASE. Medacy has expanded its pharmacist-led clinical services significantly over the last three years and we are still just scratching the surface of clinical pharmacists' potential to transform health services.
The experience and expertise of CHASE will support Medacy to realise its full potential, with our businesses sharing the same culture and values that put people first. Though we focus on different elements of healthcare delivery, I’m excited by how our complementary expertise will benefit our NHS and life science partners.”
Previous Story
